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Abstract 
Background: Self-reported measures play a crucial role in research, clinical practice and health assessment. Instru-
ments used to assess self-reported health-related quality of life (HRQoL) need validation to ensure that they measure 
what they are intended to, detect true changes over time and differentiate between subjects. A generic instrument 
measuring HRQoL adapted for use among people living with cancer in Uganda is lacking; therefore, this study aimed 
to evaluate the psychometric properties of the European Organisation for Research and Treatment of Cancer (EORTC) 
QLQ-C30 in patients with cancer in Uganda.
Methods: Adult patients with various types of cancer (n = 385) cared for at the Uganda Cancer Institute answered 
the EORTC QLQ-C30 in Luganda or English language, the two most spoken languages in the country. The two lan-
guage versions were evaluated with regard to data quality (floor and ceiling effects and missing responses), reliability 
(internal consistency) and validity (construct, known-group and criterion). Construct validity was examined through 
confirmatory factor analysis (CFA). Mean scores were compared between groups differing in disease stage to assess 
known-group validity. Criterion validity was examined according to associations between two QLQ-C30 subscales 
(Global quality of life and Physical function) and the Karnofsky Performance Scale (KPS).
Results: Floor and ceiling effects were observed for several scales in the Luganda and English versions. All EORTC 
scales with the exception of Cognitive function (Luganda α = 0.66, English α = 0.50) had acceptable Cronbach’s alpha 
values (0.79–0.96). The CFA yielded good fit indices for both versions (RMSEA = 0.08, SRMR = 0.05 and CFI = 0.93). 
Known-group validity was demonstrated with statistically significant better HRQoL reported by patients with disease 
stages I–II compared to those in stages III–IV. Criterion validity was supported by positive correlations between KPS 
and the subscales Physical function (Luganda r = 0.75, English r = 0.76) and Global quality of life (Luganda r = 0.59, 
English r = 0.72).
Conclusion: The Luganda and English versions of the EORTC QLQ-C30 appear to be valid and reliable measures and 
can be recommended for use in clinical research to assess HRQoL in adult Ugandans with cancer. However, the cogni-
tive scale did not reach acceptable internal consistency and needs further evaluation.
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Background
Cancer is expected to increase worldwide by more than 
85% by 2030 [1, 2]. Being diagnosed with cancer and 
undergoing its treatment may have a negative impact 
on patients’ health-related quality of life (HRQoL) and 
cause multiple concerns [3]. Measurements of HRQoL 
can be used for various purposes including to distinguish 
Open Access
*Correspondence:  namalallen@gmail.com
1 Department of Nursing, College of Health Sciences, Makerere University, 
Kampala, Uganda
Full list of author information is available at the end of the article
Page 2 of 11Naamala et al. Health Qual Life Outcomes          (2021) 19:131 
patients in need of actions and interventions at different 
periods during and after treatment [4].
A few studies have investigated HRQoL in persons 
suffering from cancer in East Africa using standardized 
measures. One such study conducted in Uganda assessed 
women with ovarian cancer using the abbreviated ver-
sion of the World Health Organisation Quality of Life 
instrument and they found that patients scored poorly 
across domains [5]. In Tanzania and Kenya, quality of life 
have been assessed with the questionnaire developed by 
the European Organisation for Research and Treatment 
of Cancer (EORTC): the QLQ-C30 [6]. Masika and co-
workers who assessed HRQoL with the EORTC QLQ-
C30 in the capital of Tanzania, demonstrated low overall 
HRQoL in hospitalised patients, specifically with regard 
to financial situation and pain [7]. Their findings were 
supported by results from a cross-sectional study con-
ducted in Kenya of approximately 150 women undergo-
ing palliative treatment for cervical cancer [8].
The instrument established by the EORTC, the QLQ-
C30, was originally developed in English to investigate 
HRQoL in patients participating in clinical trials [6]. 
The questionnaire is applicable in more than 70 coun-
tries worldwide including the major languages spoken in 
the Western world and Asia [9]. In Sub-Saharan Africa, 
the questionnaire is available in 9 languages: Afrikaans, 
Amharic, Ilokano, Kiswahili, Sepedi, Sotho, Xhosa, Yor-
uba and Zulu [9–12]. In Uganda no valid and reliable 
instrument for assessment of generic HRQoL in adults 
with cancer exists. Therefore, in this study, we set out to 
evaluate the psychometric properties of the Luganda and 
English versions of the EORTC QLQ-C30 in Uganda.
Methods
The study employed a cross-sectional design.
Study setting
The present study was conducted at UCI, which is the 
only public hospital providing specialised cancer services 
in Uganda. The services include screening, radiother-
apy, chemotherapy, counselling, training programmes, 
rehabilitation and palliative care. Additionally, research 
and consultation services are offered to promote bet-
ter cancer control and care in the country. The institute 
offers care for in- and outpatients and has a bed capac-
ity of more than 100 inpatients organised into five clini-
cal units: two units for children and three for adults (solid 
tumour centre, lymphoma treatment centre and an out-
patient department). Annually, UCI receives over 60,000 
new cancer cases of both men and women, of which cer-
vical cancer and Kaposi sarcoma account for 19.7% and 
13% of cases, respectively [13].
Sample
Adult (≥ 18  years) patients with cancer, treated and 
cared for at UCI, speaking Luganda or English languages, 
with physical and mental ability (this was judged by the 
respective unit in-charges), were identified for possible 
participation in the study. A total of 482 patients were 
approached and screened for eligibility during a 4-week 
period (June–July 2019). Eligible patients (n = 407) were 
asked to answer the authorized Luganda [14] or English 
versions of EORTC QLQ-C30 (version 3). Data was col-
lected by seven registered nurses who had been trained 
for the data collection procedure.
The EORTC QLQ‑C30
The EORTC QLQ-C30 version 3 consists of 30 items 
divided into nine multi-item subscales and six single 
items representing various aspects of HRQoL [6]. The 
multi-item scales include five functional scales (physi-
cal, role, emotional, cognitive and social), three symptom 
scales (fatigue, nausea/vomiting and pain) and a global 
health and quality-of-life scale (Global QoL). Addition-
ally, six single items measure impact on symptoms of 
dyspnoea, insomnia, loss of appetite, constipation, diar-
rhoea and the perceived financial impact of the disease.
All items have four response alternatives that range 
from 1 to 4 (‘not at all’, ‘a little’, ‘quite a bit’ and ‘very 
much’), with the exception of the two items comprising 
the Global QoL scale, which have a score ranging from 
1 (very poor) to 7 (excellent). According to the EORTC 
QLQ-C30 Scoring Manual, raw scores in QLQ-C30 
are linearly transformed to 0–100 point scales [15]. For 
Global health status and the five functioning status, a 
score of 100 corresponds to a high HRQoL, whereas for 
financial difficulties and the eight symptoms, a score of 
100 implies maximum difficulty or symptom burden [15, 
16].
Translation of the EORTC QLQ‑C30 to Luganda language
For the purposes of this study, the instrument (version 3) 
was translated into the Luganda language and linguisti-
cally validated by our research group in accordance with 
the procedure developed by EORTC [17]. This included 
a forward–backward procedure, involving two forward 
and two backward translators. The steps (forward trans-
lation, reconciliation and backward translation with com-
ments) were reviewed and approved by the Translational 
Unit of the EORTC Quality of Life Group before starting 
pilot testing. The preliminary Luganda version was pilot 
tested on 20 adult cancer patients, native Luganda speak-
ers treated and cared for at the Uganda Cancer Insti-
tute (UCI) [14]. The translation report was reviewed by 
Page 3 of 11Naamala et al. Health Qual Life Outcomes          (2021) 19:131  
the EORTC translation coordinator before the Luganda 
version of the EORTC QLQ-C30 was authorised by the 
EORTC Quality of Life Group [9].
Additional measures
The Karnofsky Performance Scale
All participants were assessed with the Karnofsky Per-
formance Scale (KPS) index in addition to EORTC QLQ-
C30. The KPS is an 11-point categorical scale ranging 
from 100 (normal functioning) to 0 (dead) in ten point 
increments [18]. The instrument may be used to compare 
functional abilities across populations as well as evaluat-
ing the effectiveness of different therapies [18, 19]. For 
data analysis patients were categorised into three groups 
[20], KPS of ≥ 80 reflected patients able to carry on with 
normal activity, those rated at 50–70 were unable to work 
but could take care of most personal needs while patients 
with KPS < 40 were unable to care for themselves and 
required care.
Socio‑demographic and clinical data
Demographic data were collected using study-specific 
items to assess sex, age, marital status, number of chil-
dren and household members, level of education and 
employment status. Clinical information was collected 
through medical records and included cancer diagnosis 
and stage, date of diagnosis and type of received cancer 
treatment.
Data analyses
Statistical analyses were performed in Stata version 14 
[21]. Data were analysed by language version, Luganda 
and English. Analysis of data quality included distribu-
tion of scale scores (item means and standard deviations, 
floor and ceiling effects and missing item responses). The 
raw scores were used for psychometric evaluation, with 
the exception of floor and ceiling effects, which on the 
transformed scores [15]. Floor and ceiling effects were 
calculated and considered acceptable if they did not 
exceed 15% [22]. Cronbach’s alpha was used to assess 
internal consistency. For this measure, values ≥ 0.7 are 
considered ideal; however, some researchers consider 
values < 0.70 but close to 0.60 as satisfactory [23].
Construct validity was ascertained using confirmatory 
factor analysis (CFA), which was performed to deter-
mine the adequacy of the original EORTC QLQ-C30 on 
our data by language version. The maximum likelihood 
method was used in all analyses. When, as in our case, 
hypotheses exist, based on theory and previous analyses, 
CFA is more appropriate than exploratory factor analysis 
(EFA) [24]. Standardised coefficients of ≥ 0.4 were con-
sidered acceptable [25]. Normalized mean and covariance 
residuals were evaluated and found acceptable. Model fit 
was estimated by two absolute indices of overall model 
fit: root mean square error of approximation (RMSEA) 
and standardised root mean residual (SRMR). Addition-
ally, one relative index of model fit was used: comparative 
fit index (CFI). The acceptable thresholds for these indi-
ces were defined as RMSEA = 0.05–0.08, SRMR < 0.08 
and CFI > 0.90 according to Kline’s guidelines [26]. The 
degrees of freedom were reported, but not considered as 
an indicator of model fit owing to their restrictiveness of 
being sensitive to sample size [27].
Known-group validity was evaluated by examining the 
instrument’s capacity to discriminate between patients 
differing in disease stage (stages I–II vs. stages III–IV). 
Independent t-tests were calculated to investigate poten-
tial differences in the mean scores of the EORTC QLQ-
C30 scales between the two groups. Effect sizes (ES) were 
calculated to indicate the clinical significance of possible 
differences in means, whereby ES = 0.2, 0.5–0.8 and > 0.8 
were considered small, moderate and large difference, 
respectively [22].
Criterion validity was determined by calculating Pear-
son’s correlation coefficient for two of the EORTC QLQ-
C30 subscales (Physical function and Global QoL) and 
the KPS [28]. It was hypothesised that the selected QLQ-
C30 subscales would correlate positively to KPS with 
coefficients of large magnitude [28].
Procedure
Data was collected by seven trained research assistants 
(nurses), who approached patients in the clinical units. 
Patients were identified through patient lists generated 
by the study coordinator at the wards and outpatient 
department. The lists were used to evenly distribute par-
ticipants among data collectors with the help of unit in-
charges as well as planned appointments.
Potential participants were given written and oral 
information in Luganda or English about the aim and 
procedures of the study. It was stressed that participa-
tion was voluntary and that non-participation would not 
affect care and treatment in any way. Informed consent 
was asked for, and those patients who could not provide 
consent in writing were asked to do so through thumb 
print. Due to the large number of patients seen at UCI 
who could not read or write, the questions were read to 
all patients. Additional demographic and clinical data 
were collected from patients’ clinical records at UCI.
Results
Of the 482 approached patients, 75 were excluded due 
to the following: poor health (n = 23), ongoing stag-
ing investigations (n = 15), cognitive difficulties (n = 5) 
or language barrier (n = 32). Furthermore, 22 patients 
refused to participate, whereas 385 (66% women and 34% 
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men aged 18–84 years) consented to participate and sub-
sequently answered the EORTC QLQ-C30 in Luganda 
(n = 217) or English (n = 168) by interview, resulting in a 
response rate of 95%.
The sociodemographic characteristics of the sam-
ple are presented in Table 1. The clinical characteristics 
of the patients are presented in Table  2 and reveal that 
most participants (65%) were in-patients with cancers in 
stages III and IV. Furthermore, approximately 60% had 
received chemotherapy, and one quarter had received 
radiotherapy.
Data quality
There were no missing item responses. Item means 
within subscales were roughly equivalent, and the stand-
ard deviations were close to 1 with the exception of 
the Global QoL scale. All response alternatives were 
used for all items. Floor effects in the Luganda version 
ranged between 5.5 and 53.0%, and ceiling effects ranged 
between 3.7 and 27.2% (Table 3). The corresponding floor 
effects for the English version ranged from 3.6 to 58.3%, 
and ceiling effects from 3.6 to 29.8%.
Reliability
Cronbach’s α ranged from 0.66 to 0.94 for the Luganda 
version and from 0.50 to 0.96 for the English version 
(Table 3). The Cognitive function scale had the lowest α 
(0.66, Luganda version; 0.50, English version).
Construct validity
The CFA was performed separately on responses 
from the two versions: Luganda (n = 217) and English 
(n = 168), please see Figs.  1 and 2. Both versions pro-
vided statistically significant models: namely, Luganda 
χ2 = 490.07 (p < 0.001) and English version χ2 = 452.16 
(p < 0.001) with standard factor loading estimates rang-
ing from 0.59 to 0.96 for the Luganda version and from 
0.46 to 0.97 for the English version. The fit statistics of 
the CFA conducted on the Luganda version provided 
an RMSEA of 0.08 (90% CI 0.07–0.09), an SRMR of 0.05 
and a CFI of 0.93; the corresponding values for the Eng-
lish version were RMSEA = 0.08 (90% CI 0.07–0.09), 
SRMR = 0.05 and CFI = 0.93.
Table 1 Socio-demographic characteristics by language version, Luganda (n = 217) and English (n = 168)
Data collected at Uganda Cancer Institute 2019
a Differences in proportions tested with χ2 statistics




χ2a Df P value
Sample size 385 (100) 217 (100) 168 (100)
Sex 1.10 1 0.294
Female 254 (66) 148 (68.2) 106 (63.1)
Male 131 (34) 69 (31.8) 62 (36.9)
Marital status 2.96 1 0.085
Married/cohabiting 217 (56.4) 114 (52.5) 103 (61.3)
Widowed/single/divorced 168 (43.6) 103 (47.5) 65 (38.7)
Home region 65.58 4  < 0.001
Northern 56 (14.5) 7 (3.2) 49 (29.2)
Eastern 63 (16.4) 28 (12.9) 35 (20.8)
Western 90 (23.4) 56 (25.8) 34 (20.2)
Central 171 (44.4) 123 (56.7) 48 (28.6)
Non-Ugandan 5 (1.3) 3 (1.4) 2 (1.2)
Education level 46.83 3  < 0.001
Tertiary 65 (16.9) 15 (6.9) 50 (29.8)
Secondary 123 (31.9) 63 (29) 60 (35.7)
Primary 143 (37.1) 100 (46.1) 43 (25.6)
None 54 (14) 39 (18) 15 (8.9)
Occupation 17.58 3 0.003
Employed/farmer/business 323 (83.9) 181 (83.4) 142 (84.5)
Student 14 (3.6) 5 (2.3) 9 (5.4)
Housewife 8 (2.1) 4 (1.8) 4 (2.4)
None 40 (10.4) 27 (12.4) 13 (7.7)
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Known‑group validity
Mean values for early (I–II) and late (III–IV) stages 
of the disease (both language versions) are presented 
in Table  4. In two of the five functional subscales and 
the Global QoL scale, statistically significant differ-
ences (both languages) were detected between patients 
with late stage disease, who rated worse functioning 
compared to those in early stages. In the multi-item 
symptom scales the same pattern was seen with more 
symptoms among those in late stages, however, only 
statistically significant for the English versions. ES 
ranged between small and medium, with Physical func-
tion displaying the highest ES (Luganda 0.56, English 
0.70). Some participants (n = 78) were still undergo-
ing staging investigations and were not included in the 
analysis.
Criterion‑based validity
Positive correlations were revealed between the KPS 
and the subscales of Physical function (Luganda ver-
sion r = 0.75, English version r = 0.76) and Global QoL 
(Luganda version r = 0.59, English version r = 0.72), all 
tests were statistically significant (< 0.001) and the coef-
ficients of large magnitude.
Discussion
This study reported on the psychometric evaluation of 
the English and Luganda versions of the generic EORTC 
QLQ-C30 when used in cancer care in Uganda. Most 
importantly, the instrument demonstrated satisfactory 
validity in terms of construct and known-group validity 
as well as in criterion validity. However, even though the 
overall data quality was good with acceptable reliability 
Table 2  Clinical characteristics of patients at Uganda Cancer Institute, Luganda language (N = (217) and English language (N = 168)
DF, Degrees of freedom
a Missing data







χ2b Df P value
Sample size 385 (100) 217 (100) 168 (100)
Clinical setting 0.39 1 0.533
In Patient 257 (66.8) 142 (65.4) 115 (68.5)
Out Patient 128 (33.2) 75 (34.6) 53 (31.5)
Cancer type 11.61 9 0.236
Cervical 92 (23.9) 60 (27.6) 32 (19.0)
Breast 68 (17.7) 32 (14.7) 36 (21.4)
KS 43 (11.2) 28 (12.9) 15 (8.9)
Leukemia 26 (6.7) 14 (6.5) 12 (7.1)
Prostate 22 (5.7) 12 (5.5) 10 (6.0)
Oesophageal 20 (5.2) 8 (3.7) 12 (7.1)
Lymphoma 18 (4.7) 7 (3.2) 11 (6.5)
Lung 8 (2.1) 5 (2.3) 3 (1.8)
Ovarian 8 (2.1) 4 (1.8) 4 (2.4)
Other 80 (20.8) 47 (21.7) 33(19.6)
Cancer Stage 1.39 1 0.499
Early (I & II) 99 (25.7) 51 (23.5) 48 (28.6)
Late (III & IV) 208 (54) 122 (56.2) 86 (51.2)
Not  reporteda 78 (20.3) 44 (20.3) 34 (20.3)
Type of treatment 0.02 1 0.813
Chemotherapy 235 (61) 130 (59.9) 105 (62.5)
Radiotherapy 94 (24.4) 51 (23.5) 43 (25.6)
Surgery 38 (9.9) 21 (9.7) 17 (10.1)
Palliative 15 (3.9) 12 (5.5) 3 (1.8)
No treatment yet 3 (< 1) 3 (< 1) –
Grouped KPS 0.41 2 0.813
 ≤ 40 58 (15.1) 34 (15.7) 24 (14.3)
50–70 162(42.1) 93 (42.9) 69 (41.1)
 ≥ 80 165 (42.9) 90 (41.5) 75 (44.6)
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(internal consistency) for all but one scale, considerable 
high floor and ceiling effects were detected for some 
scales, and this tendency merits some concern.
The study had a large sample of adult men and 
women cared for at UCI, including both in- and out-
patients. While all hospitalized patients during the data 
collection period were approached indicating a census 
study, the recruitment of outpatients were not con-
ducted in the same systematic way due to a large num-
ber of patients in the waiting areas. The participants of 
the study are still considered to be representative of the 
patients cared for at UCI which also is reflected by the 
vast majority speaking Luganda or English. Approxi-
mately 7% of the approached patients did speak neither 
Luganda nor English which is expected with more than 
40 spoken languages in the country. Most Ugandans 
are peasant farmers who speak and conduct small scale 
businesses in local languages. No significant differences 
were found regarding gender, marital status and clinical 
characteristics with regard to language versions. This 
was expected considering the fact that cancer stage, 
type of treatment or status of KPS are independent of 
the language one speaks.
With regard to data quality, all response alternatives 
were used for all items (data not shown), suggesting 
that the response scale was sufficient. However, floor 
effects of approximately 30%–50% were observed for 
the Role function, Social function and Nausea/vomit-
ing scales, with a similar pattern observed for both lan-
guage versions. Additionally, ceiling effects exceeding 
25% were observed in the Cognitive function and Pain 
scales for both language versions. Furthermore, ceil-
ing effect of the English version of the Emotional func-
tion scale was 21%. This distribution may indicate that 
a large proportion of patients in an advanced disease 
Table 3 Descriptive statistics for the subscales of EORTC QLQ-C30 by language version, Luganda (N = 217) and English (N = 168)
PF; Physical function, RF; Role function, EF; Emotional function, CF; Cognitive function, SF; Social function, FA; Fatigue, NV; Nausea and vomiting, PA; Pain, Global QoL; 
Globalquality-of-life
a Means and SDs calculated on raw scores; higher scores indicate better HRQoL and more symptoms
b Floor and ceiling effects calculated on transformed scores
Subscales (no of items) Meana (SD) Range of item means (SD) Floor/ceiling  effectb, % Cronbach’s α
PF (5)
Luganda 2.47 (0.91) 1.74–3.10 (1.10–1.19) 8.8/9.2 0.86
English 2.31 (0.95) 1.61–2.90 (1.01–1.24) 7.7/14.9 0.88
RF (2)
Luganda 3.00 (1.02) 2.89–3.10 (1.05–1.09) 35.5/11.5 0.91
English 2.77 (1.10) 2.77–2.77 (1.13–1.17) 28/18.5 0.90
EF (4)
Luganda 2.29 (0.96) 2.16–2.38 (1.08–1.12) 9.7/13.8 0.89
English 2.26 (0.98) 2.15–2.52 (1.08–1.15) 8.9/21.4 0.91
CF (2)
Luganda 2.17 (1.00) 2.12–2.21 (1.13–1.18) 11.1 /26.3 0.66
English 2.03 (0.91) 1.90–2.15 (1.08–1.15) 5.4/29.8 0.50
SF (2)
Luganda 3.03 (1.03) 3.02–3.03(1.10–1.16) 41.0/9.7 0.79
English 3.08 (0.98) 3.01–3.15(1.01–1.12) 42.9/6.5 0.81
FA (3)
Luganda 2.66 (0.96) 2.52–2.84 (1.04–1.08) 7.8/18.0 0.89
English 2.50 (0.98) 2.42–2.55(1.09–1.16) 14.3/9.5 0.85
NV (2)
Luganda 1.82 (1.07) 1.72–1.93(1.07–1.16) 53.0/11.1 0.92
English 1.61 (0.92) 1.44–1.79 (0.88–1.08) 58.3/5.4 0.85
PA (2)
Luganda 2.83 (0.99) 2.80–2.86(1.05–1.10) 9.2/27.2 0.83
English 2.70 (1.08) 2.70–2.70(1.10–1.18) 16.7/24.4 0.89
Global QOL (2)
Luganda 4.02 (1.51) 4.02–4.02 (1.54–1.56) 5.5/3.7 0.94
English 3.93 (1.53) 3.89–3.98 (1.55–1.57) 3.6/3.6 0.96






























































































Fig. 1 Model of confirmatory factor analysis (CFA) indicating standardized loadings on the factors of the Luganda version of the EORTC QLQ-C30 
(n = 217)






























































































Fig. 2 Model of confirmatory factor analysis (CFA) indicating standardized loadings on the factors of the English version of the EORTC QLQ-C30 
(n = 168)
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stage experienced diminished functioning regarding 
role and social functioning due to fatigue and pain.
The high floor effects for the Nausea/vomiting scale 
could indicate poor ability to differentiate between 
no symptoms and mild symptoms; however, based on 
clinical experience, it might probably be partially a con-
sequence of low prevalence of these symptoms in this 
patient population [16]. The high floor effects seen for 
the Nausea/vomiting scale was puzzling considering 
that approximately 60% of the patients were currently 
on chemotherapy and nausea and vomiting are well-
known side effects of chemotherapy [29].
All scales but one had satisfactory reliability. The cog-
nitive function scale displayed a Cronbach’s alpha of 
0.50 for the English version and of 0.66 for the Luganda 
version. A low alpha coefficient for the cognitive scale 
has been reported in other studies in East Africa [7, 12, 
30]. It has been argued that this may to some extent be 
due to the small number of items in the scale. One of 
the two items measuring cognitive function assesses 
the ability to concentrate on things (‘like reading a 
newspaper or watching television’), activities that may 
appear inappropriate for Ugandans with cancer since 
newspapers and televisions are not available to patients 
at UCI. Furthermore, the literature has shown that 
Ugandans have low reading literacy [31]. The other 
item in the scale asks about memory: ‘Have you had dif-
ficulty remembering things’. Thus, it is understandable 
that the two items may not be highly correlated and 
subsequently results in a low alpha value.
The CFA supported the notion that the EORTC QLQ-
C30 measures the intended nine multi-item scales of 
HRQoL. Standardised factor loadings and the goodness 
of fit for outputs of the Luganda and English versions 
demonstrated satisfactory results, suggesting strong con-
struct validity [23]. However, literature shows that the 
value of Cronbach’s alpha coefficients is highly influenced 
by the number of items in the scale, that alpha increases 
with the number of items in the domain. Six of the nine 
multi-item scales consist of only two items which is 
known to negatively impact on internal consistency of a 
scale [32], still satisfying results were seen for all scales 
with the exception of Cognitive function.
The instrument demonstrated known-group validity 
as the EORTC QLQ-C30 was able to successfully dis-
criminate between early and late stages of cancer among 
participants, such that patients with advanced disease 
demonstrated poorer HRQoL than those with early 
stages of the disease. Furthermore, ES revealed that the 
detected statistically significant differences were clinically 
relevant. Furthermore, the physical function and Global 
QoL scales were both associated with the KPS, with large 
correlation coefficients indicating criterion validity [23].
Strengths and limitations
This is the first study of HRQoL using the generic meas-
ure EORTC QLQ-C30 to be performed in Uganda. The 
study had a large representative sample of adult men 
and women cared for at UCI, including both in- and 
outpatients. The study was conducted using the most 
commonly used languages in the country. Still, a small 
proportion of patients could not speak and understand 
Luganda or English and were therefore excluded and 
if this group perceives the measure’s items in a differ-
ent way is not known. Future studies carried out in 
Table 4 Significant differences in self-reported HRQoL by 
disease stage, stage I-II (Luganda n = 51, English n = 48) 
compared to stage III-IV (Luganda n = 122, English n = 86)
Data collected at Uganda Cancer Institute 2019
ªMean scores ranges from 0 to 100, higher scores in functional scales reflect 
better HRQoL and higher scores in symptom scale more symptoms










Global quality of life
Luganda 57.52 (26.94) 46.58 (24.64) 0.010 0.43
English 55.21 (23.67) 43.99 (26.12) 0.015 0.44
Physical function
Luganda 60.39 (27.14) 44.01 (30.19)  < 0.001 0.56
English 68.19 (25.55) 46.51 (33.48)  < 0.001 0.70
Role function
Luganda 43.14 (37.14) 26.37 (31.77) 0.003 0.50
English 49.65 (34.81) 36.24 (37.33) 0.043 0.37
Cognitive function
Luganda 61.44 (33.91) 56.42(34.51) 0.382 0.15
English 69.10 (28.35) 61.82 (33.12) 0.202 0.23
Emotional function
Luganda 55.56 (33.44) 52.80 (33.02) 0.619 0.08
English 62.33 (29.52) 55.23 (35.59) 0.243 0.21
Social function
Luganda 21.57 (29.87) 30.33 (33.95) 0.111 − 0.27
English 25.69 (30.36) 30.23 (32.59) 0.430 − 0.14
Fatigue
Luganda 52.29 (34.38) 61.57 (30.81) 0.083 − 0.29
English 42.13 (28.35) 56.85 (34.23) 0.013 − 0.46
Nausea/vomiting
Luganda 20.59 (34.41) 32.24 (36.60) 0.054 − 0.32
English 13.19 (22.53) 24.42 (34.27) 0.044 − 0.37
Pain
Luganda 58.17 (36.57) 66.80 (31.67) 0.121 − 0.26
English 47.92(32.37) 62.60 (35.69) 0.020 − 0.42
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Uganda are recommended to use educated interpreters 
to be able to include all Ugandan patients irrespective 
of spoken language. Furthermore, despite high efforts 
to reach patients during the data collection period 
we had difficulties to systematically include outpa-
tients due to a large number of patients in the waiting 
rooms. Despite using trained interviewers instructed 
to include any outpatients available in the waiting area 
inclusion bias cannot be ruled out. The issue was dis-
cussed throughout the data collection and the inter-
viewers were encouraged to reach out to all kind of 
patients (sexes, all ages, various health statuses, being 
accompanied or coming alone). Moreover, the cross-
sectional design of the study prohibited any possibility 
to examine the instrument’s test–retest reliability.
Conclusions
This first psychometric evaluation of the English and 
Luganda versions of the 30-item EORTC QLQ-C30 in a 
Ugandan context is promising. The instrument appears 
to be a valid and reliable measure, with the exception 
of the Cognitive function scale, in which we recom-
mend that one item be rephrased to better suit a Ugan-
dan context. Furthermore, the floor effects noted for 
Role and Social functioning, reflecting low function, 
as well as the ceiling effect for the Pain subscale (high 
pain) may be an obstacle when conducting comparative 
studies. Apart from caution in interpreting cognitive 
function, the instrument is recommended for clinical 
and epidemiological researchers to study the HRQoL of 
adult Ugandans with cancer.
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